- RecruitingPHASE1, PHASE2
A Study of Amivantamab Alone or in Addition to Other Treatment Agents in Participants With Head and Neck Cancer
This study looks at new ways to treat head and neck cancer using a drug called Amivantamab, sometimes combined with other treatments. It aims to find out if these treatments are safe and how well they work for people with different types of head and neck cancer.
For: Squamous Cell Carcinoma of Head and NeckUnited States · China · France - Active not recruitingPHASE3
A Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib in Locally Advanced or Metastatic Non-Small Cell Lung Cancer
This study is looking at two new drug combinations, amivantamab and lazertinib, compared to a standard drug, osimertinib, for people in the UK with advanced non-small cell lung cancer that has a specific genetic change (EGFR mutation).
For: Carcinoma, Non-Small-Cell LungUnited States · Argentina · Australia - Active not recruitingPHASE1
Study of Amivantamab, a Human Bispecific EGFR and cMet Antibody, in Participants With Advanced Non-Small Cell Lung Cancer
This study looks at a new drug, Amivantamab, alone or with other treatments, for certain types of advanced lung cancer. We want to find the safest and most effective dose, and see how well it works.
For: Non-Small-Cell Lung CancerUnited States · Australia · Canada - RecruitingPHASE3
A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer
This study compares two treatments for advanced left-sided bowel cancer that hasn't spread. It looks at how long people stay disease-free when given a new drug called amivantamab with chemotherapy, versus a standard drug called cetuximab with chemotherapy.
For: Colorectal NeoplasmsUnited States · Belgium · Brazil - RecruitingPHASE3
A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy
This study is for people with advanced bowel cancer where previous chemotherapy hasn't worked. It compares a new drug called amivantamab, plus standard FOLFIRI chemotherapy, against other established treatments (cetuximab or bevacizumab) with FOLFIRI, to see which works best.
For: Colorectal NeoplasmsUnited States · Australia · Belgium - RecruitingPHASE2
A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
This study looks at new ways to treat advanced lung cancer that has a specific genetic change (EGFR mutation). It tests combinations of new drugs, amivantamab and lazertinib, or amivantamab with standard chemotherapy, to see how well they work.
For: Carcinoma, Non-Small-Cell LungUnited States · Belgium · Finland - RecruitingPHASE3
A Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck Cancer
This study is looking at a new treatment for head and neck cancer that has come back or spread. It combines a new drug, amivantamab, with standard treatments to see if it works better than standard care alone to fight the cancer.
For: Squamous Cell Carcinoma of Head and NeckUnited States · Australia · Austria - Active not recruitingPHASE1, PHASE2
A Study of Amivantamab and Capmatinib Combination Therapy in Unresectable Metastatic Non-small Cell Lung Cancer
This study is looking at a new way to treat a type of lung cancer called non-small cell lung cancer. It combines two medicines, amivantamab and capmatinib, to see how well they work together and what the best dose is.
For: Carcinoma, Non-Small-Cell LungUnited States · Brazil · Canada - Active not recruitingPHASE2
Amivantamab, Lazertinib and Bevacizumab in Patients With EGFR-mutant Advanced Non-small Cell Lung Cancer With Progression on Previous Third-generation EGFR-TKI
This study looks at a new combination of three drugs (Amivantamab, Lazertinib, and Bevacizumab) for advanced non-small cell lung cancer. It's for patients whose cancer has grown even after previous treatment with a similar drug. The study wants to see how well this new combination works and if it's safe.
For: Non Small Cell Lung CancerFrance · Italy · Netherlands - Active not recruitingPHASE3
A Study of Amivantamab and Lazertinib in Combination With Platinum-Based Chemotherapy Compared With Platinum-Based Chemotherapy in Patients With Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non- Small Cell Lung Cancer After Osimertinib Failure
This study looks at new drug combinations for advanced lung cancer (non-small cell lung carcinoma) that has specific genetic changes (EGFR mutation) and has stopped responding to a previous treatment called osimertinib. It compares these new drug combinations with standard chemotherapy.
For: Carcinoma, Non-Small-Cell LungUnited States · Argentina · Belgium - Active not recruitingPHASE3
A Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy, Compared With Carboplatin-Pemetrexed, in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Characterized by Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions
This study looks at a new combination of treatments for a type of advanced lung cancer. It compares a drug called amivantamab plus standard chemotherapy to chemotherapy alone, to see if the combination works better at stopping the cancer from growing.
For: Carcinoma, Non-Small-Cell LungUnited States · Australia · Belgium - RecruitingPHASE1, PHASE2
A Study of Amivantamab Monotherapy and in Addition to Standard-of-Care Chemotherapy in Participants With Advanced or Metastatic Colorectal Cancer
This study is testing a new drug, amivantamab, for advanced bowel cancer. It checks how well it works alone or with standard chemotherapy, and how safe it is. The study aims to find better ways to treat advanced bowel cancer.
For: Advanced or Metastatic Colorectal CancerUnited States · Belgium · Canada - Active not recruitingPHASE1, PHASE2
A Study of Combination Therapy With Amivantamab and Cetrelimab in Participants With Metastatic Non-small Cell Lung Cancer
This study looks at a new combination of two medicines, amivantamab and cetrelimab, for advanced lung cancer. It aims to find the best dose and see how well it works in people whose cancer has spread and who have already had other treatments.
For: Carcinoma, Non-Small-Cell LungUnited States · Brazil · Italy - RecruitingPHASE2
A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer
This study looks at a new way to give a cancer drug called amivantamab, by injection under the skin instead of through a drip. It aims to see how well it works and if it's safe for people with advanced lung cancer, especially those with specific genetic changes.
For: Carcinoma, Non-small-Cell LungUnited States · Brazil · China - RecruitingPHASE1
5G-EMERALD: Amivantamab in Malignant Brain Tumours
This study, called 5G-EMERALD, is testing a new drug called amivantamab for people with certain types of aggressive brain tumours. It aims to see if the drug is safe and if it helps shrink tumours, especially in patients whose tumours have a specific genetic feature.
For: Malignant Primary Gliomas · Glioblastoma Multiform (Grade IV Astrocytoma) · Diffuse Hemispheric Glioma, H3 G34-MutantUnited Kingdom - Active not recruitingPHASE1, PHASE2
A Study of Combination Therapy With Amivantamab and Docetaxel in Participants With Metastatic Non-small Cell Lung Cancer
This study is testing a new combination of two medicines, amivantamab and docetaxel, for people with advanced non-small cell lung cancer. The aim is to find the best dose and see how well this combination works.
For: Carcinoma, Non-Small-Cell LungUnited States · Taiwan · Turkey (Türkiye) - RecruitingPHASE2
A Modular Multi-Basket Trial to Improve Personalized Medicine in Cancer Patients (Basket of Baskets)
This study looks at new ways to treat advanced cancers by matching specific drugs to changes found in a patient's tumour genes. It tests three different drugs – atezolizumab, futibatinib, and amivantamab – to see how well they shrink tumours in different groups of patients.
For: Advanced Solid TumorFrance · Germany · Italy